Why Tranylcypromine Still Matters
Tranylcypromine (Parnate) is one of the most effective antidepressants ever brought to market, and it sits nearly untouched at the back of the pharmacy. Fewer than one in fifty psychiatrists prescribes MAOIs with any regularity. An entire generation of clinicians has trained, graduated, and built careers without ever writing for one. And yet, for the patient who has failed four antidepressants, for the patient with atypical depression who sleeps twelve hours and still can't get out of bed, for the patient whose life has narrowed to a chair by the window, tranylcypromine is frequently the drug that works when nothing else did.
The reasons for its neglect have almost nothing to do with efficacy. MAOIs came up in the 1950s and 1960s, before controlled trials were routine, so their evidence base looks thinner on paper than it is in practice. They carry two genuinely frightening interactions (hypertensive crisis and serotonin syndrome) that acquired an outsized, almost mythological reputation. The tyramine diet, drilled into everyone in training, sounds like a life sentence of culinary deprivation. And there is no marketing budget, no rep, no reminder that this old generic exists. The drug simply fell out of collective muscle memory.
This guide is about putting tranylcypromine back on the table. It is a safe, high-yield antidepressant when you educate the patient properly, honor a genuinely short list of dietary and drug restrictions, respect the washout windows, and monitor blood pressure. Do those things and you have access to one of the few genuine rescue options in treatment-resistant and atypical depression: a drug that routinely produces remission after everything else has failed.
A note on where it fits: tranylcypromine is not a first-line agent. It earns its place after multiple failures, and it demands a patient who can partner with you on diet and drug safety. But within that population, the response rates are among the best in psychiatry. The tragedy is not that MAOIs are dangerous; the data say the serious events are rare. The tragedy is that thousands of patients who would remit on an MAOI never get offered one, because their prescriber was afraid of a diet.
How to Use Tranylcypromine With Confidence
Let's be honest about why this drug gets skipped. It isn't that clinicians decided their treatment-resistant patients don't need it. It's that the MAOI carries a specific bundle of fears: the tyramine crisis, serotonin syndrome, the washout logistics, the diet, the sheer unfamiliarity, and each fear, on its own, is enough to make a busy prescriber reach for the fifth SSRI instead. If that's you, this section is for you.
The good news: prescribing tranylcypromine safely is entirely achievable in any outpatient practice. The serious events are genuinely rare in educated patients, and the whole safety architecture reduces to a small number of concrete habits. Dr. Cole, who prescribed MAOIs for over thirty years at McLean, saw exactly one catastrophic hypertensive event in that entire span, and it happened when a patient eloped from care and took a massive Sudafed overdose. That is the shape of the real risk: not a slice of aged cheddar, but a patient who abandons the rules entirely.
The Core Problem (And the Core Solution)
The reason MAOIs feel scary is that safety depends on the patient doing things correctly out in the world: avoiding certain foods, avoiding certain over-the-counter drugs, telling every other provider they're on an MAOI. In most practices, that education is delivered once, verbally, in a rushed visit, and then left to chance.
The solution is to make the education systematic, written, and reinforced, and to give the patient a concrete sense of control over their own safety. Give every patient a written MAOI wallet card and a one-page diet-and-drug sheet. Walk through it together at the start. Reinforce it at every visit. And, this is the move experienced MAOI prescribers swear by, give the patient nifedipine 10 mg to carry as an "amulet." More on the pharmacology below, but the psychological effect is real: a patient who carries their own emergency treatment feels like an agent in their own safety rather than a passenger waiting for disaster. That single gesture does more for tolerability and adherence than any amount of reassurance.
The patients who genuinely cannot be on an MAOI are the ones who cannot or will not follow the rules: active stimulant users, patients with impulsive overdose risk who can't be safely dispensed, patients too cognitively impaired to track a diet. That's a real but small group. Most treatment-resistant patients, given a clear one-page sheet and treated as a partner, comply far better than you fear. Don't let the exceptions disqualify the rule.
Addressing the Specific Fears
The modern tyramine story is far less scary than the one you were taught. Most published diet lists predate accurate tyramine measurement and are wildly over-inclusive. The genuinely dangerous foods are a short list: aged cheeses, cured/aged meats, tap (draft) beer, marmite/concentrated yeast extracts, sauerkraut, and fava beans. Fresh mozzarella on a fresh pizza is fine. A glass of wine is fine for most. The diet is a real constraint, not a monastic vow. Teach the short list, give it in writing, and give the nifedipine amulet.
This one is about drug lists and washouts, not luck. The absolute no-fly list is short and memorable: no SSRIs, no SNRIs, no clomipramine, no meperidine, no dextromethorphan, no St. John's wort, no L-tryptophan. Honor a real washout before you start (5 half-lives of the prior antidepressant, which means a full 5 weeks off fluoxetine), and honor a 2-week washout after stopping tranylcypromine before starting anything serotonergic. If you know the no-fly list and you respect the washout clock, serotonin syndrome is a preventable event, not a random one.
Legitimate concern, and you plan for it. Bridge the drug-free gap with a benzodiazepine for distress and sleep. Bupropion and mirtazapine are compatible with the eventual MAOI and can be used thoughtfully. The gap is a managed interval, not a void, and for a patient who has already failed four drugs, a two-to-five-week bridge toward a medication that might actually work is a reasonable trade.
Then hand the patient a validated written sheet and review it together: you don't have to lecture from memory. The excellent free reference by Ken Gillman at psychotropical.info gives the modern, evidence-based tyramine list. Print it. Use it. The patient becomes the expert on their own plate.
This is why the wallet card matters. The card tells any ED, surgeon, dentist, or pharmacist that the patient is on an MAOI, which flags the meperidine, the sympathomimetics, and the anesthetic cautions before harm is done. Systematize it: card in the wallet, the fact in the chart's allergy/alert field, and a standing instruction to the patient to announce it before any new prescription or procedure.
The Mindset Shift
Here is the reframe that makes tranylcypromine prescribable for any conscientious clinician:
The MAOI isn't dangerous because it has rules. The MAOI is safe because you follow the rules, and the rules are short, learnable, and largely in the patient's hands. Every powerful medication asks something of the prescriber. Clozapine asks for weekly blood counts. Lithium asks for levels and a narrow window. The MAOI asks for patient education about a short food list, a short drug list, and a washout clock. Meet that requirement and you unlock a drug that, in the treatment-resistant and atypical populations, remits patients whom the entire modern pharmacopeia left behind. Your most treatment-resistant patients deserve to have this drug on the table, not buried under a 1960s reputation.
Part 1: Indications: Who Is Tranylcypromine For?
FDA-Approved Use
- Major depressive disorder, particularly when other antidepressants have failed (treatment-resistant depression).
The Evidence-Based Clinical Uses
Treatment-resistant depression: the core indication. This is where tranylcypromine earns its keep. In a classic study of 47 patients with depression refractory to two or more tricyclics, tranylcypromine produced a ~50% response rate, remarkable in a population defined by prior failure. MAOIs sit at the later stages of essentially every TRD algorithm, and the mistake most clinicians make is waiting far too long to get there. If a patient has failed roughly four adequate antidepressant trials, the MAOI conversation is not exotic, it's overdue.
Atypical depression: where MAOIs may be uniquely good. Atypical features (increased appetite, increased sleep [hypersomnia], leaden paralysis, mood reactivity, and rejection sensitivity) define a subgroup where older MAOIs have historically outperformed tricyclics (2006 meta-analysis, Henkel et al.). The advantage over SSRIs is less clear-cut in modern data, but many clinicians still reach for an MAOI specifically for the sleepy, heavy, appetite-driven atypical presentation that never quite responds to serotonergic agents.
Anxious and agitated depression. Tranylcypromine is used for depression accompanied by prominent anxiety and agitation. That said, if anxiety is the dominant feature, phenelzine is the better-evidenced MAOI (see comparisons below); it has the larger track record in anxiety-spectrum illness.
Off-label and pilot-data uses. Tranylcypromine and the MAOI class have supportive (if smaller) evidence in:
- Social anxiety disorder: a genuine MAOI strength; phenelzine has a large effect size across 5 RCTs, larger than typically seen with SSRIs.
- Panic disorder: particularly when comorbid with social anxiety.
- Dysthymic disorder: demonstrated efficacy.
- PTSD: pilot data.
- Bulimia: pilot data.
Who Is a Good Candidate
- Patients with treatment-resistant depression after multiple adequate antidepressant trials.
- Patients with atypical features (hypersomnia, hyperphagia, leaden paralysis, rejection sensitivity).
- Patients who can reliably follow dietary and drug restrictions.
- Patients with the cognitive capacity and life stability to partner on safety.
Who Is a Poor Candidate
- Patients unable or unwilling to follow dietary restrictions.
- Active stimulant or cocaine users (hypertensive crisis risk).
- Patients requiring multiple serotonergic agents that can't be stopped.
- Pheochromocytoma (absolute contraindication).
- Uncontrolled hypertension or significant cardiovascular disease (relative; orthostasis and crisis risk).
- Patients who cannot be safely dispensed medication if impulsive-overdose risk is high.
The single most common reason "treatment-resistant" patients haven't responded is that they were never adequately treated: wrong doses, too-short trials, or never escalated to a genuine MAOI trial. Before you conclude a patient is beyond help, ask whether they've ever had an adequate tranylcypromine trial pushed to 40–60 mg (or higher) for a full 4–6 weeks. Many haven't.
Part 2: Before You Start: Workup and Candidacy
Unlike lithium or the TCAs, tranylcypromine requires no routine drug-level monitoring and no baseline ECG. The workup is about safety education and cardiovascular baseline, not labs.
Baseline Assessment
| Item | Why |
|---|---|
| Baseline blood pressure, sitting and standing | Orthostatic hypotension is the most common problematic side effect; you need a baseline to track against |
| Heart rate (sitting/standing) | Orthostatic tracking |
| Cardiovascular history | CVD and uncontrolled HTN are relative contraindications |
| Medication reconciliation: every prescription, OTC, and supplement | The serotonergic no-fly list and sympathomimetic risks live here; this is the most important safety step |
| Substance use screen | Active stimulant/cocaine use is a hard stop |
| Dietary-compliance assessment | Can this patient realistically follow the tyramine list? |
| Pregnancy status | Limited pregnancy safety data (see Special Populations) |
No routine baseline labs, no mandatory ECG. Levels can be measured only if compliance is in question, rarely needed.
The Washout Before You Start
This is a workup step, not an afterthought. Before the first tranylcypromine tablet:
- Taper the prior antidepressant over 1–2 weeks (or stop abruptly for the long-half-life agents), then wait 5 half-lives of that drug before starting.
- Fluoxetine: because of its long half-life and that of its active metabolite, wait ~5 weeks.
- Vortioxetine: wait roughly 2–3 weeks; it can be stopped abruptly.
- Most other SSRIs/SNRIs/TCAs: 1–2 weeks after taper.
- Bridge the gap with a benzodiazepine for distress and insomnia if needed.
The washout is not a formality you can shortcut for a struggling patient. Starting an MAOI on top of residual serotonergic drug is exactly how serotonin syndrome happens. Put the start date on the calendar, count the half-lives, and hold the line, especially the full 5 weeks off fluoxetine.
Part 3: How to Start and Dose
Formulation
Tranylcypromine comes in exactly one size: 10 mg tablets. There is no extended-release, no liquid, no patch. The single-strength simplicity is actually an advantage: no dose confusion, no formulation switching. You titrate by counting tablets.
Starting Dose and Titration
- Start: 10 mg (one tablet) in the morning, or 10 mg BID (morning and early afternoon). Divided daytime dosing reduces both orthostasis and insomnia.
- Titrate slowly, every 3–7 days as tolerated. Slow titration is specifically about avoiding orthostatic hypotension, which is the rate-limiting side effect.
- A workable schedule: 10 mg BID for ~2 weeks → 20 mg BID by weeks 2–3 → 40 mg/day by ~week 4. Hold at 40 mg for about 2 weeks and assess response before pushing higher.
- Avoid late-afternoon/evening dosing where possible: tranylcypromine is often stimulating, and late doses drive insomnia. Keep the last dose to early afternoon.
Target Dose
| Situation | Typical daily dose |
|---|---|
| Usual therapeutic target | 40–60 mg/day |
| Maximum labeled dose | 60 mg/day |
| Expert high-dose (off-label, TRD) | Some specialists (e.g., Jay Amsterdam) push to ~120 mg/day, reporting fewer side effects and better response at higher doses in refractory cases |
- Dose-response is real. The most common cause of a "failed" MAOI trial is an inadequate dose. If a patient tolerates the drug but hasn't responded, the answer is usually more, not a switch.
- Divided dosing (BID/TID) is generally preferable to once-daily; it smooths orthostasis.
Give the MAOI a genuine trial before you abandon it. That means pushing to at least 40–60 mg/day and holding for a full 4–6 weeks. Under-dosing and short trials are how this drug gets an undeserved reputation for not working. If your patient is tolerating 60 mg with no response, high-dose strategies (up to ~120 mg/day in expert hands) are a legitimate next step before you conclude the trial failed.
Part 4: Monitoring
Tranylcypromine monitoring is clinical, not laboratory. There are no routine blood levels, no required labs, and no mandatory ECG. What you monitor is blood pressure, tolerability, and adherence to the safety rules.
Blood Pressure
- Check BP at every office visit, sitting and standing (after standing 2–3 minutes).
- Teach home BP monitoring. Have the patient record sitting and standing BP and heart rate, especially during titration.
- You will find yourself watching for orthostatic hypotension far more often than for hypertension: low BP is the common, dose-limiting problem; hypertensive crisis is the rare, dramatic one.
Visit Cadence
- First 2–4 weeks: frequent visits (weekly is reasonable) during titration to track orthostasis, insomnia, and early response.
- Every visit: reinforce dietary and drug restrictions. This is not one-and-done education; repeat it, and re-check the OTC/supplement list each time.
- Assess weight, sexual function, sleep, and any serotonergic or sympathomimetic exposures at each contact.
What You Do NOT Need
- No routine drug levels (measure only if adherence is genuinely in question).
- No baseline or routine ECG (unlike TCAs).
- No renal/thyroid/hepatic panels on a schedule; order labs only as clinically indicated.
Part 5: Side Effects and How to Manage Them
The governing principle mirrors the rest of psychiatry: most tranylcypromine side effects are dose-related and manageable, and the common ones are nuisances (orthostasis, insomnia) rather than dangers. The dangerous events (hypertensive crisis, serotonin syndrome) are rare and largely preventable, covered separately in Toxicity and Interactions. One genuine advantage of tranylcypromine over its MAOI cousins: less weight gain and less sedation than phenelzine.
Orthostatic Hypotension (the most common problematic effect)
More frequent and more troublesome than hypertension. It's the reason you titrate slowly.
Management:
- Titrate slowly and use divided dosing (BID/TID) rather than a single large dose.
- Increase fluid intake: aim for ~8 glasses of water per day.
- Add dietary salt if not contraindicated.
- Compression/support stockings.
- Lower or remove concurrent antihypertensives where safe.
- Reduce the tranylcypromine dose if orthostasis is limiting.
- Severe/refractory cases: fludrocortisone, roughly 0.1 mg titrated as needed (some sources cite higher PRN regimens); use the lowest effective dose and monitor for edema and supine hypertension.
Insomnia
Tranylcypromine is often stimulating (though, notably, some clinicians find it sedating in individual patients; the effect is idiosyncratic). Insomnia is less common with tranylcypromine than with some classic MAOIs, but still frequent.
Management:
- Shift dosing earlier: morning and early afternoon; avoid late-day doses.
- Add a hypnotic if needed. Standard FDA-approved hypnotics (zolpidem, eszopiclone, benzodiazepines, etc.) are compatible, with one exception: doxepin/Silenor is not safe with MAOIs (serotonergic risk).
Weight Gain
A relative strength of tranylcypromine: less weight gain than phenelzine or isocarboxazid. When it occurs, manage with diet, activity, and the usual metabolic counseling.
Sexual Dysfunction
Occurs at a moderate rate, roughly comparable to SSRIs. Options include dose reduction, timing adjustments, or augmentation strategies; some clinicians use bupropion (MAOI-compatible) or a psychostimulant (with monitoring) where appropriate.
Agitation
A moderate amount of agitation/activation can occur, consistent with the drug's stimulating profile. Dose adjustment and timing usually address it; a short-term benzodiazepine can bridge.
Edema
Peripheral edema can occur and is managed with a thiazide diuretic (hydrochlorothiazide); monitor BP, since diuretics compound orthostasis.
Paresthesias
Reported, and thought to reflect pyridoxine (vitamin B6) depletion, a class effect of hydrazine and related MAOIs. Supplement vitamin B6 if paresthesias emerge.
Two side effects dominate the early weeks and both have straightforward fixes: orthostasis (slow titration, divide the dose, hydrate, salt, stockings) and insomnia (dose early, add a safe hypnotic, not doxepin). If you pre-empt these two with the patient before they start, you keep them on the drug long enough to see the antidepressant benefit.
Part 6: Toxicity and Boxed Warnings
Tranylcypromine's dangers are not the slow, level-dependent toxicity of lithium; they are two acute, dramatic, and largely preventable events, plus a rare discontinuation phenomenon.
1. Hypertensive Crisis (the "cheese reaction")
Mechanism. MAOIs block the breakdown of dietary tyramine in the gut. Tyramine floods the circulation, displaces norepinephrine from nerve terminals, and, layered on top of the MAOI-driven accumulation of norepinephrine, produces a "double whammy" surge in blood pressure. Tranylcypromine's amphetamine-like structure makes it the classic MAOI most prone to this reaction with tyramine and adrenergic agents.
What the patient feels. Sudden, severe headache; patients describe it as their "head going to split." It may be accompanied by neck stiffness, palpitations, sweating, and nausea. Anecdotally, some patients report headaches in the late afternoon with no obvious trigger.
Acute management:
- Nifedipine 10 mg immediate-release: bite/chew and swallow; repeat in 30 minutes if no relief. This is the "amulet" strategy: patients carry it and can act faster than an ED visit would allow.
- Labetalol is an alternative in a monitored setting.
- Chlorpromazine 50 mg is an older option (effective but sedating, with ~24 hours of malaise, less favored).
- Do NOT use phentolamine reflexively as an outpatient move: too aggressive for self-management.
- A caution on the ED: patients who present to a waiting room often find symptoms and BP normalizing on their own before they're seen. The crisis is frequently self-limited once tyramine clears, which is exactly why patient-carried nifedipine and reassurance matter.
Prevention is the whole game: the tyramine diet plus avoidance of sympathomimetics (below).
2. Serotonin Syndrome
Mechanism. Combining an MAOI with a serotonergic agent produces excess synaptic serotonin: agitation, hyperthermia, clonus, rigidity, autonomic instability, and, at the extreme, death. This risk is more common and more severe with MAOIs than with any other drug class.
Prevention: honor the serotonergic no-fly list and the washout windows (see Interactions). This is a preventable event.
3. Discontinuation Psychotic Delirium (rare)
Abrupt discontinuation of tranylcypromine can, rarely, trigger a psychotic delirium. This is uncommon but real, and it's the reason you taper rather than stop abruptly (see Discontinuation).
Overdose
MAOI overdose is serious: delayed-onset hypertension, hyperthermia, autonomic instability, and neuromuscular hyperactivity that can evolve over many hours, with a characteristically delayed and prolonged course that warrants observation even when the patient initially looks well.
- Serotonin syndrome. With serotonergic agents.
- Hypertensive crisis. With tyramine and sympathomimetics.
- Suicidality warning. The antidepressant class warning regarding increased suicidal ideation in patients under 25 applies.
- Rare psychotic delirium. On abrupt discontinuation.
Part 7: Drug and Dietary Interactions: The Heart of MAOI Safety
This is where MAOI prescribing lives or dies. Master these lists and the drug is safe; ignore them and it is dangerous. Teach them, write them down, and re-check them at every visit.
The Serotonergic No-Fly List (Serotonin Syndrome Risk)
Absolutely contraindicated, do not combine:
- SSRIs and SNRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, duloxetine, etc.)
- Clomipramine: the one TCA that is clearly dangerous (highly serotonergic).
- Meperidine (Demerol): a classic, potentially fatal combination.
- Dextromethorphan: hidden in countless OTC cough/cold products.
- St. John's wort and L-tryptophan.
- Doxepin/Silenor as a hypnotic.
- Ziprasidone: the one antipsychotic that cannot be combined with an MAOI.
- Use only with caution/expert monitoring: buspirone, carbamazepine, cyclobenzaprine, and triptans carry theoretical-to-real serotonergic additivity; generally avoid or monitor closely.
The Sympathomimetic / Hypertensive-Crisis List
Avoid, can precipitate hypertensive crisis:
- OTC decongestants: pseudoephedrine and phenylephrine (in cold/flu/allergy products).
- Cocaine, amphetamines, MDMA (drugs of abuse).
- Excessive alcohol.
- Other adrenergic/sympathomimetic agents.
The Tyramine Diet: Shorter Than You Were Taught
Most historical diet lists predate accurate tyramine measurement and are dramatically over-inclusive. The modern, evidence-based restriction is a short list of genuinely high-tyramine foods.
- Aged cheeses (cheddar, blue, parmesan, aged gouda, etc.)
- Cured, aged, or fermented meats (dry sausage, salami, aged/spoiled meats)
- Tap/draft (unpasteurized) beer
- Concentrated yeast extracts (Marmite, Vegemite)
- Sauerkraut and other fermented cabbage
- Fava (broad) beans
- Spoiled or improperly stored protein foods of any kind
- Fresh cheeses (mozzarella, cream cheese, cottage cheese, ricotta): fresh pizza with mozzarella is safe
- Bottled/canned beer and wine in moderation
- Fresh meats, fresh produce
Ken Gillman's comprehensive, evidence-based MAOI diet-and-drug review at psychotropical.info is the modern gold standard. Print the current tyramine list from a validated source rather than reciting the 1960s version from memory.
Combinations That Are Safe (and Useful)
Not everything is forbidden. In expert hands, these are used with tranylcypromine:
- Bupropion: non-serotonergic; safe.
- Mirtazapine: reported safe.
- Certain sedating tricyclics (trimipramine, amitriptyline): reported safe in clinical practice, though caution and expertise are warranted.
- Trazodone: officially contraindicated, but Dr. Cole and colleagues treated ~80 patients with low-dose trazodone atop an MAOI for sleep without incident; used off-label in experienced hands.
- Psychostimulants (methylphenidate, dextroamphetamine): despite the theoretical hypertensive concern, experienced clinicians (Dr. Cole) have used them without hypertensive crisis, notably to treat MAOI-induced afternoon sleepiness. Use with caution and monitoring.
Augmentation Strategies (When the MAOI Alone Isn't Enough)
- Lithium: the augmentation strategy with the best evidence; a natural pairing for MAOI partial responders.
- Second-generation antipsychotics: usable except ziprasidone.
- Psychostimulants: carefully monitored.
- Trazodone: for sleep, off-label, expert hands.
- Do not augment with SSRIs, SNRIs, or clomipramine: serotonin syndrome.
Surgery and Anesthesia
MAOIs interact with anesthetic and pain agents (notably meperidine and sympathomimetic pressors). Any surgery or procedure requires the anesthesia team to know the patient is on an MAOI; this is what the wallet card is for. Historically MAOIs were stopped before surgery, but with modern anesthesia many procedures can proceed safely with appropriate agent selection; coordinate rather than reflexively discontinue.
The most dangerous interactions in real life aren't exotic; they're an OTC cold medicine (pseudoephedrine or dextromethorphan) and a serotonergic antidepressant restarted too soon. Two habits prevent almost all harm: tell the patient to clear every new medication, prescription or OTC, with you or a pharmacist first, and enforce the washout clock in both directions.
Part 8: Special Populations
Pregnancy
Limited safety data: MAOIs are old and poorly studied in pregnancy. They are generally avoided when safer, better-characterized alternatives exist. There are specific concerns about hypertensive effects and drug interactions during labor and delivery (anesthetics, pressors). If a patient's severe, treatment-resistant depression has only ever responded to tranylcypromine, the decision becomes an individualized risk/benefit discussion in coordination with obstetrics, but for most patients, a better-studied agent is preferred in pregnancy.
Lactation
Transfer into breast milk is not well characterized. Given the unknowns and the potential for infant exposure, caution is warranted; this is a benefit-versus-risk decision with pediatric input, and generally not a first choice during breastfeeding.
Elderly
- Orthostatic hypotension is the dominant concern: falls, fractures, cerebral/cardiac ischemia, and confusion.
- Start low, titrate more slowly (some geriatric experts raise the dose only every ~2 weeks), targeting a conservative dose within the usual range (roughly 30 to 60 mg/day) as tolerated.
- Home BP monitoring is essential.
- That said, tranylcypromine remains a legitimate option in geriatric TRD (the same efficacy that makes it valuable in younger refractory patients applies here), provided orthostasis is respected.
Renal Impairment
Accumulation risk raises the likelihood of orthostatic hypotension and toxicity. Dose reduction and closer monitoring are prudent.
Hepatic Impairment
Also an accumulation risk. Reduce the dose and monitor closely.
Pediatric
Not typically used in children or adolescents: limited safety and efficacy data, and the dietary-compliance requirement is a practical barrier in this age group.
Part 9: Discontinuation and Switching
Stopping Tranylcypromine
- Taper slowly, over about 2 weeks. Do not stop abruptly; rare cases of abrupt-discontinuation psychotic delirium are the reason.
- After stopping, wait a full 2 weeks before lifting dietary/drug restrictions or starting a new (especially serotonergic) antidepressant. The enzyme inhibition is irreversible: MAO activity recovers only as the body synthesizes new enzyme, which takes about 1–2 weeks. Until then, the patient is still functionally "on" an MAOI even though they've stopped the pills; the diet and drug rules stay in force.
The 2-week post-discontinuation window is the one everyone forgets. A patient who stops tranylcypromine on Monday is not safe to start sertraline on Tuesday. The enzyme has to regenerate. Put the "restriction end date" and the "earliest new-antidepressant date" in writing when you stop the drug.
Switching
Onto tranylcypromine (from another antidepressant): taper 1–2 weeks, then wait 5 half-lives: 5 weeks for fluoxetine, 2–3 weeks for vortioxetine, 1–2 weeks for most others. Bridge with a benzodiazepine.
Off tranylcypromine (to another antidepressant): taper over ~2 weeks, then wait the full 2 weeks for enzyme recovery before introducing the next agent.
Part 10: Tranylcypromine vs the Alternatives
Within the MAOI Class
vs Phenelzine (Nardil). The two most-used oral MAOIs, and the choice usually comes down to profile:
- Tranylcypromine: less sedation, less weight gain, more likely to be activating/cause insomnia, and higher hypertensive risk with tyramine/adrenergics (amphetamine-like structure). Favored for apathetic, lethargic, anergic depression.
- Phenelzine: more sedating, more weight gain, more sexual dysfunction, but more anxiolytic and better-evidenced for anxiety-spectrum illness (social anxiety, panic) and best-studied for atypical depression; also the most affordable MAOI.
- Rule of thumb: Parnate for apathy and lethargy; Nardil for anxiety and agitation.
vs Isocarboxazid (Marplan). Similar in form (10 mg tablets, up to 60 mg/day) and roughly equivalent efficacy to Parnate/Nardil; reportedly better tolerated than phenelzine in some studies. Reacquired and relaunched in the US by Validus in 2007 but relatively expensive (~$3/tablet). Reasonable if a patient has a prior good response or you can source it affordably.
vs Selegiline transdermal (Emsam). The genuinely different MAOI:
- At the 6 mg/24h patch, NO dietary restrictions are required (the transdermal route bypasses gut MAO, so tyramine handling is preserved).
- Much cleaner side-effect profile: minimal weight gain, sedation, and sexual dysfunction.
- The catch: at 9–12 mg, dietary restrictions return, and, critically, Emsam lacks the efficacy data in TRD and atypical depression that the oral MAOIs have. For your hardest refractory cases, the oral drugs remain better supported. Emsam is the option for a diet-noncompliant or side-effect-sensitive patient, not the heavy-hitter for stage-4 TRD.
vs Moclobemide (not available in US). Reversible, MAO-A-selective, no meaningful dietary restrictions, but reportedly less effective than the irreversible non-selective agents, and unavailable in the United States anyway.
Against the Broader Antidepressant Field
Tranylcypromine's argument is simple and specific: it is a rescue drug. It is not competing with SSRIs for first-line use; it competes with augmentation, TMS, ECT, ketamine/esketamine, and the other stage-4 options for the patient who has already failed the standard agents. In that arena, its response rates in treatment-resistant and atypical depression are strong, its cost is trivial (generic), and it reaches patients whom serotonergic drugs never touched. Its cost is the diet, the drug list, and the washouts: a real but learnable price.
So why is it underused? Only ~2% of psychiatrists prescribe MAOIs regularly. The reasons are the 1960s reputation, the diet mythology, unfamiliarity bred by a generation of training without hands-on MAOI experience, and the absence of any marketing. None of these are clinical reasons. For the right patient, tranylcypromine belongs earlier in the algorithm than most clinicians place it.
Mechanism: The Short Version
Tranylcypromine is a non-selective, irreversible inhibitor of both MAO-A and MAO-B. By knocking out these enzymes, it blocks the breakdown of norepinephrine, serotonin, and dopamine, raising synaptic levels of all three. Among the classic MAOIs, tranylcypromine has the strongest dopaminergic effect, which likely contributes to its activating, pro-motivational quality and its usefulness in anergic, apathetic depression.
Structurally, tranylcypromine is amphetamine-like, which explains two things at once: its stimulating clinical profile and its heightened tendency toward hypertensive reactions with tyramine and adrenergic agents. Because the enzyme inhibition is irreversible, restored MAO activity depends on synthesizing new enzyme, hence the ~2-week recovery period after discontinuation, during which the interaction cautions persist.
The Bedside Cheat Sheet
Who it's for
- TRD after ~4 antidepressant failures; atypical depression (hypersomnia, hyperphagia, leaden paralysis, rejection sensitivity); anxious depression; social anxiety
- Requires a patient who can follow the diet and drug rules
Starting & dosing
- 10 mg tablets only. Start 10 mg AM or 10 mg BID; titrate every 3–7 days
- Path: 10 mg BID → 20 mg BID (wk 2–3) → 40 mg/day (~wk 4); hold 2 wks, assess
- Target 40–60 mg/day (max labeled 60); experts go to ~120 mg in refractory TRD
- Divided dosing and no late-day doses (orthostasis + insomnia)
- Under-dosing/short trials are the #1 cause of "failure": push the dose, give it 4–6 weeks
Workup & monitoring
- No routine labs, no ECG, no drug levels
- Baseline + ongoing BP sitting/standing; teach home BP monitoring
- Frequent visits first 2–4 weeks; reinforce diet/drug rules every visit
The washout clock (both directions)
- Onto Parnate: taper prior drug 1–2 wks, then wait 5 half-lives: fluoxetine = 5 wks, vortioxetine 2–3 wks, most others 1–2 wks. Bridge with a benzo
- Off Parnate: taper ~2 wks, then wait 2 full weeks (enzyme regeneration) before any serotonergic drug or lifting restrictions
Two dangers, both preventable
- Hypertensive crisis: tyramine + sympathomimetics. Warn re: sudden "splitting" headache. Give nifedipine 10 mg to carry (bite/swallow, repeat in 30 min)
- Serotonin syndrome: no SSRIs/SNRIs, clomipramine, meperidine, dextromethorphan, St. John's wort, L-tryptophan, doxepin/Silenor, ziprasidone
The short tyramine list
- Avoid: aged cheese, cured/aged meats, tap/draft beer, Marmite/Vegemite, sauerkraut, fava beans, spoiled protein
- Safe: fresh cheeses (mozzarella), bottled beer/wine in moderation, fresh foods. Use a validated modern list, e.g. psychotropical.info
Common side effects
- Orthostasis (most common): slow titration, divide dose, hydrate, salt, stockings; fludrocortisone if severe
- Insomnia: dose early; safe hypnotics OK (not doxepin)
- Less weight gain/sedation than phenelzine. Sexual dysfunction ~SSRI-level. Paresthesias → vitamin B6. Edema → HCTZ
Safe partners / augmentation
- Compatible: bupropion, mirtazapine, some sedating TCAs (trimipramine), low-dose trazodone for sleep (expert hands), stimulants (with caution)
- Augment with lithium (best evidence) or SGAs (not ziprasidone)
Don't forget
- Clear every new Rx/OTC/supplement first (pseudoephedrine, dextromethorphan hide in cold meds)
- Wallet card + alert flag in chart; tell any surgeon/dentist/ED
- Taper to stop (abrupt stop → rare psychotic delirium)
Tranylcypromine asks more of the prescriber than the average antidepressant: a medication reconciliation, a washout clock, a short diet, a patient who can partner on safety, and a habit of reinforcing the rules. In exchange it offers something most of our newer drugs cannot: genuine remission in the patient who has failed everything else, and a particular edge in the atypical, sleepy, anergic depression that serotonergic agents so often leave untouched. The serious events are rare and, almost without exception, preventable by the small set of habits laid out here. Used with respect for its two dangers and confidence in its short list of rules, tranylcypromine is not a dusty relic to be feared: it is one of the most powerful tools in the treatment-resistant armamentarium, and it deserves to be on the table long before the patient has run out of hope.